Yahong Pharmaceuticals: Net loss of 419 million yuan in 2025

2026-03-29 16:30:12

YaHong Biopharma Company Announcement: In fiscal year 2025, it achieved operating revenue of 277 million yuan, up 37.49% year over year; net profit attributable to owners of the parent company was -419 million yuan, compared with -384 million yuan in the same period last year. The company’s loss during this reporting period is mainly because its core products are still in R&D or in the stage of listing approval and review, so the company continues to maintain relatively high R&D spending, and because the company steadily advances upgrades to its commercialization system and actively prepares for the commercialization of new products, among other related investments.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes